Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT06864195

A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions

Led by Imperial College London · Updated on 2025-03-07

750

Participants Needed

1

Research Sites

106 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease. Who can take part? Adults aged 18 or older who: Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved? Participants will: Give a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \& Risks This research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants. There are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK. Who is funding the study? The study is funded by Rosetrees and Stoneygate Trust. Contact Information Email: vocal-study@imperial.ac.uk Phone: +44 (0)20 7594 3396

CONDITIONS

Official Title

A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female adults aged 18 years or older
  • Participants diagnosed with histologically or radiologically confirmed hepatocellular carcinoma or cholangiocarcinoma
  • Participants with liver cirrhosis confirmed by imaging or biopsy
  • Participants with primary sclerosing cholangitis confirmed by MRCP, ERCP, or biopsy
  • Participants with non-specific gastrointestinal symptoms but a normal liver scan
Not Eligible

You will not qualify if you...

  • Active infection or use of immunosuppressive medications within the last eight weeks
  • History of another cancer within the past five years
  • Previous liver surgery
  • Prior chemotherapy, radiotherapy, or surgery for liver cancer
  • Medical conditions that prevent breath sample collection
  • Pregnancy
  • Unable to provide informed written consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Imperial College London

London, United Kingdom

Actively Recruiting

Loading map...

Research Team

G

Georgios Karagiannidis, MBBS(Hon)

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here